Home › MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. To Develop Small Molecules Targeting Sarcopenia And Cachexia
 

Keywords :   


MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. To Develop Small Molecules Targeting Sarcopenia And Cachexia

2014-07-30 10:12:15| drugdiscoveryonline Home Page

MYOS Corporation("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it has entered into a research and development agreement with Cloud Pharmaceuticals, Inc

Tags: small agreement corporation develop

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
19.05Gillette Venus Announces Ambassadors Ahead of the Olympic and Paralympic Games Paris 2024
19.05Eastern North Pacific Tropical Weather Outlook
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05Atlantic Tropical Weather Outlook
More »